Mga Batayang Estadistika
| CIK | 1420108 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Glucose Health, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 28, 2023 |
GLUCOSE HEALTH, INC. 609 SW 8th Street, Suite 600 Bentonville, Arkansas 72712 GLUCOSE HEALTH, INC. 609 SW 8th Street, Suite 600 Bentonville, Arkansas 72712 June 28, 2023 VIA EDGAR Christie Wong Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Glucose Health, Inc. Registration Statement on Form S-1 Originally Filed June 1, 2022 File No. 333-265335 Dear Ms. Wong: Glucose Health, Inc. (the “Company”) hereby requests, |
|
| January 9, 2023 |
Nominating and Corporate Governance Committee Charter EXHIBIT 99.3 Glucose Health, Inc. Charter of the Nominating and Corporate Governance Committee of the Board of Directors The purpose of the Nominating and Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Glucose Health, Inc. (the “Company”) shall be as set forth in this charter (the “Charter”). The Committee has been delegated authority by the Board to: ( |
|
| January 9, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 9, 2023 As filed with the U.S. Securities and Exchange Commission on January 9, 2023 Registration No. 333-265335 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Glucose Health, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2833 90-1117742 (State or other jurisdiction of incorp |
|
| January 9, 2023 |
Form of Representative’s Warrant Agreement EXHIBIT 4.1 Form of Representative’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FO |
|
| January 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GLUCOSE HEALTH, INC. |
|
| January 9, 2023 |
EXHIBIT 10.12 Form of Lock-Up Agreement for Officers, Directors, and Holder(s) of more than 5% Common Stock [●], 202[●] EF HUTTON, division of Benchmark Investments, LLC as Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, an officer, director and/or holder of more than 5% of |
|
| January 9, 2023 |
Consent of Sarah Berman, dated November 24, 2022 EXHIBIT 10.11 CONSENT OF CHIEF ACCOUNTING OFFICER NOMINEE In connection with the filing by Glucose Health, Inc. (the “Company”) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents to |
|
| January 9, 2023 |
Consent of Heidi Skolnik, October 17, 2022 EXHIBIT 99.7 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Glucose Health, Inc. (the “Company”) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents, as required by Rule |
|
| January 9, 2023 |
Form of Underwriting Agreement EX-1.1 2 glucex11.htm FORM OF UNDERWRITING AGREEMENT EXHIBIT 1.1 UNDERWRITING AGREEMENT between GLUCOSE HEALTH, INC., and EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC AS REPRESENTATIVE OF THE SEVERAL UNDERWRITERS TABLE OF CONTENTS Page Section 1. Purchase and Sale of Firm Shares and Over-Allotment Option 3 Section 2. Representations and Warranties of the Company 5 Section 3. Covenants of the |
|
| January 9, 2023 |
EXHIBIT 99.1 GLUCOSE HEALTH, INC. Charter of the Audit Committee of the Board of Directors I. Audit Committee Purpose The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Glucose Health, Inc. (the “Company”) is to oversee the processes of accounting and financial reporting of the Company and the audits and financial statements of the Company. The Committe |
|
| January 9, 2023 |
EXHIBIT 99.4 CODE OF ETHICS OF GLUCOSE HEALTH, INC. 1. Introduction The Board of Directors of Glucose Health, Inc. (the “Company”) has adopted this code of ethics (the “Code”), which is applicable to all directors, officers and employees of the Company, with the intent to: · promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between perso |
|
| January 9, 2023 |
EXHIBIT 3.6 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLUCOSE HEALTH, INC. Glucose Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: That the Board of Directors of the Corporation has adopted and approved pursuant to Section 242 of the General Corporation Law of the |
|
| January 9, 2023 |
Compensation Committee Charter EXHIBIT 99.2 Glucose Health, Inc. Charter of the Compensation Committee of the Board of Directors I. Authority and Composition The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Glucose Health, Inc. (the “Company”) is established pursuant to Article IV of the Bylaws of the Company. Committee members are appointed annually by the Board on the recommendation of t |
|
| September 6, 2022 |
As filed with the U.S. Securities and Exchange Commission on September 2, 2022 As filed with the U.S. Securities and Exchange Commission on September 2, 2022 Registration No. 333-265335 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Glucose Health, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2833 90-1117742 (State or other jurisdiction of inco |
|
| September 6, 2022 |
EXHIBIT 10.6 SERVICES AGREEMENT THIS AGREEMENT is made as of July 1, 2021, between Glucose Health, Inc. (?Company?) and BTB Management Company (?Consultant?) and super cedes a previous agreement dated October 1, 2014, between the Company and Murray Fleming, and all provisions set forth in this Agreement shall govern. 1. SERVICES. Consultant agrees to perform the services of management of corporate |
|
| August 5, 2022 |
Form of Independent Director Agreement between Glucose Health, Inc. and Robert Sipper EXHIBIT 10.10 INDEPENDENT DIRECTOR AGREEMENT This INDEPENDENT DIRECTOR AGREEMENT is dated August 1, 2022 (the ?Agreement?) by and between GLUCOSE HEALTH, INC, a Delaware corporation (the ?Company?), and ROBERT SIPPER, an individual (the ?Director?). WHEREAS, the Company proposes to appoint the Director upon the consummation of its prospectus offering filed on Form S-1 with the Securities and Excha |
|
| August 5, 2022 |
As filed with the U.S. Securities and Exchange Commission on August 5, 2022 As filed with the U.S. Securities and Exchange Commission on August 5, 2022 Registration No. 333-265335 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Glucose Health, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2833 90-1117742 (State or other jurisdiction of incorpo |
|
| August 5, 2022 |
Form of Independent Director Agreement between Glucose Health, Inc. and William Sipper EXHIBIT 10.9 INDEPENDENT DIRECTOR AGREEMENT This INDEPENDENT DIRECTOR AGREEMENT is dated August 1, 2022 (?Agreement?), by and between GLUCOSE HEALTH, INC, a Delaware corporation (the ?Company?), and WILLIAM SIPPER, an individual (the ?Director?). WHEREAS, the Company proposes to appoint the Director upon the consummation of its prospectus offering filed on Form S-1 with the Securities and Exchange |
|
| August 5, 2022 |
Convertible Promissory Note issued to BTB Management Company, dated April 1, 2016 EXHIBIT 10.6 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, IDENTIFIED BY [***], HAS BEEN EXCLUDED FROM THIS DOCUMENT PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT GLUCOSE HEALTH, INC. TREATS AS PRIVATE OR CONFIDENTIAL. THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR W |
|
| June 1, 2022 |
As filed with the U.S. Securities and Exchange Commission on June 1, 2022 As filed with the U.S. Securities and Exchange Commission on June 1, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Glucose Health, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2833 90-1117742 (State or other jurisdiction of incorporation or organization) (Pr |
|
| June 1, 2022 |
Convertible Promissory Note issued to BTB Management Company, dated April 1, 2016 EXHIBIT 10.6 THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR WITH ANY STATE SECURITIES COMMISSION. THE SECURITY EVIDENCED BY THIS PROMISSORY NOTE IS RESTRICTED AND MAY NOT BE OFFERED, RESOLD, PLEDGED OR TRANSFERRED EXCEPT PURSUANT TO REGISTRATION UNDER THE ACT OR AN AVAILABLE EXEMPTION ESTABLISHED TO THE SATISFACTION OF THE COMPANY AND IN C |
|
| June 1, 2022 |
Form of Series E Preferred Stock Purchase Agreement EXHIBIT 10.5 Stock Purchase Agreement GLUCOSE HEALTH, INC. THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) is entered into as of February 11, 2021 (the ?Closing Date?), by and between GLUCOSE HEALTH, INC., a Nevada corporation (the ?Company?) and each of the purchaser(s) as set forth on the signature pages hereof (each, a ?Purchaser? and collectively, the ?Purchasers?). Each of the Company and eac |
|
| June 1, 2022 |
Consent of Director Nominee, May 18, 2022 EXHIBIT 99.5 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Glucose Health, Inc. (the ?Company?) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), the undersigned hereby consents, as required by Rule |
|
| June 1, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GLUCOSE HEALTH, INC. |
|
| June 1, 2022 |
Consulting agreement by and between Cascadia Managing Brands, LLC, dated February 1, 2022 EXHIBIT 10.8 AGREEMENT THIS AGREEMENT made and entered into as of February 1, 2022 (hereinafter referred to as the ?Effective Date?), by and between CASCADIA MANAGING BRANDS, LLC, a Delaware Limited Liability Company, having its principal place of business at 120 East Main Street, Suite 375, Ramsey, NJ 07446 (?CMB?) and Glucose Health, Inc., a Nevada Corporation, having its principal place of busi |
|
| June 1, 2022 |
Form of Series D Preferred Stock Purchase Agreement EXHIBIT 10.4 Stock Purchase Agreement GLUCOSE HEALTH, INC. THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) is entered into effective as of June 17, 2020 (the ?Closing Date?), by and between GLUCOSE HEALTH, INC., a Nevada corporation (the ?Company?) and each of the purchasers as set forth on the signature pages hereof (each, a ?Purchaser? and collectively, the ?Purchasers?). Each of the Company and |
|
| June 1, 2022 |
Form of Series B Preferred Stock Purchase Agreement EXHIBIT 10.2 Stock Purchase Agreement GLUCOSE HEALTH, INC. (Purchaser) THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) is entered into as of May 1, 2019 (the ?Effective Date?), by and between GLUCOSE HEALTH, INC., a Nevada corporation (the ?Company?) and [ ] (?Purchaser?). Each of the Company and Purchaser may be referred to herein individually as a ?Party? and collectively as the ?Parties.? RECIT |
|
| June 1, 2022 |
Form of Series C Preferred Stock Purchase Agreement EXHIBIT 10.3 Stock Purchase Agreement GLUCOSE HEALTH, INC. THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) is entered into effective as of April 30, 2020 (the ?Closing Date?), by and between GLUCOSE HEALTH, INC., a Nevada corporation (the ?Company?) and each of the purchasers as set forth on the signature pages hereof (each, a ?Purchaser? and collectively, the ?Purchasers?). Each of the Company an |
|
| June 1, 2022 |
Certificate of Conversion, Effective March 11, 2022 EXHIBIT 3.2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
|
| June 1, 2022 |
Amended and Restated Bylaws of Glucose Health, Inc. EXHIBIT 3.4 AMENDED AND RESTATED BYLAWS OF GLUCOSE HEALTH, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Glucose Health, Inc. (the ?Corporation?) shall be fixed in the Corporation?s certificate of incorporation, as the same may be amended from time to time (the ?Certificate of Incorporation?). 1.2 OTHER OFFICES. The Corporation?s board of |
|
| June 1, 2022 |
Articles of Conversion, Effective March 11, 2022 EXHIBIT 3.1 |
|
| June 1, 2022 |
Certificate of Correction, April 13, 2022 EXHIBIT 3.5 CERTIFICATE OF CORRECTION TO THE CERTIFICATE OF INCORPORATION OF GLUCOSE HEALTH, INC. Glucose Health, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?) DOES HEREBY CERTIFY: 1. The name of the Corporation is Glucose Health, Inc. 2. That a Certificate of Incorporation was filed with the Secretary of |
|
| June 1, 2022 |
Amended and Restated Certificate of Incorporation of Glucose Health, Inc., March 29, 2022 EX-3.3 6 glucex33.htm AMENDED AND RESTATED CERTIFICATE OF INCORPORATION EXHIBIT 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLUCOSE HEALTH, INC. ARTICLE I The name of the Corporation is Glucose Health, Inc. (the “Corporation”). ARTICLE II The address of the registered office of the Corporation in the State of Delaware is 1201 N. Market Street, Suite 2300, Wilmington, New Castle County |
|
| June 1, 2022 |
EXHIBIT 10.7 SERVICES AGREEMENT THIS AGREEMENT, is made as of April 1, 2022, between Glucose Health, Inc. (?Company?) and BTB Management Company (?Consultant?) and super cedes a previous agreement dated July 1, 2021, between the Company and Murray Fleming, and all provisions set forth in this Agreement shall govern. 1. SERVICES. Consultant agrees to perform the services of management of corporate |
|
| June 1, 2022 |
Form of Plan and Agreement of Merger EXHIBIT 2.1 PLAN AND AGREEMENT OF MERGER BETWEEN GLUCOSE HEALTH MERGER SUB, INC. (A DELAWARE CORPORATION) AND GLUCOSE HEALTH, INC. (A DELAWARE CORPORATION) THIS PLAN AND AGREEMENT OF MERGER (this ?Agreement?) is entered into as of the day of March, 2022, by and between Glucose Health Merger Sub, Inc., a Delaware corporation (?Merger Sub?), and Glucose Health, Inc., a Delaware corporation (the ?Com |
|
| June 1, 2022 |
Certificate of Merger, March 29, 2022 EXHIBIT 2.2 CERTIFICATE OF MERGER OF GLUCOSE HEALTH MERGER SUB, INC. (a Delaware corporation) WITH AND INTO GLUCOSE HEALTH, INC. (a Delaware corporation) Pursuant to Section 251 of the General Corporation Law of the State of Delaware The undersigned does hereby certify: FIRST: The name of the surviving corporation is Glucose Health, Inc., a Delaware corporation, and the name of the corporation bei |
|
| June 1, 2022 |
Consent of Director Nominee, May 18, 2022 EXHIBIT 99.4 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Glucose Health, Inc. (the ?Company?) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), the undersigned hereby consents, as required by Rule |
|
| April 16, 2018 |
GLUC / Glucose Health, Inc. FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-55439 GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its |
|
| April 2, 2018 |
GLUC / Glucose Health, Inc. NT 10-K UNITED STATES SEC FILE NUMBER SECURITIES AND EXCHANGE COMMISSION 000-55439 Washington, D. |
|
| November 14, 2017 |
GLUC / Glucose Health, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of registrant a |
|
| August 21, 2017 |
GLUC / Glucose Health, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of registrant as spe |
|
| August 14, 2017 |
glucnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55439 CUSIP NUMBER 379894108 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form |
|
| May 15, 2017 |
Glucose Health FORM 10-Q (Quarterly Report) gluc10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2017 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of regi |
|
| April 11, 2017 |
Letter from ANC dated April 11, 2017. glucex161.htm EXHIBIT 16.1 April 11, 2017 U.S. Securities and Exchange Commission Office of the Chief Accountant 100F Street Northeast Washington, DC 20549-2000 RE: Glucose Health, Inc. File No. 000-55439 Dear Sir or Madam: We have read Item 4.01 of Form 8-K dated April 6, 2017 of Glucose Health, Inc. (?the Registrant?) and are in agreement with the statements contained therein as it pertains to o |
|
| April 11, 2017 |
gluc8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 6, 2017 Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55439 90-1117742 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| March 28, 2017 |
Glucose Health FORM 10-K (Annual Report) gluc10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2016 o Transition Report under Section 14 or 15 (d) of The Securities Exchange Act of 1934 For the transition period from N/A to N/A GLUCOSE HEALTH, INC. (Exact name of registrant as spec |
|
| December 21, 2016 |
Glucose Health FORM 10-Q (Quarterly Report) gluc10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of |
|
| November 14, 2016 |
glucnt10q.htm UNITED STATES SEC FILE NUMBER SECURITIES AND EXCHANGE COMMISSION 000-55439 Washington, D.C. 20549 CUSIP NUMBER 379894108 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on |
|
| August 22, 2016 |
Glucose Health FORM 10-Q (Quarterly Report) gluc10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of regis |
|
| August 22, 2016 |
Glucose Health FORM 10-Q (Quarterly Report) gluc10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of regis |
|
| August 15, 2016 |
glucnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55439 CUSIP NUMBER FORM 12b-25 379894108 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form |
|
| August 15, 2016 |
glucnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55439 CUSIP NUMBER FORM 12b-25 379894108 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form |
|
| May 23, 2016 |
Glucose Health FORM 10-Q (Quarterly Report) gluc10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of regi |
|
| May 16, 2016 |
glucnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55439 CUSIP NUMBER FORM 12b-25 379894108 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form |
|
| April 14, 2016 |
Glucose Health FORM 10-K (Annual Report) gluc10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT UNDER SECTION 14 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from N/A to N/A GLUCOSE HEALTH, INC. (Exact name of registr |
|
| March 30, 2016 |
glucnt10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55439 CUSIP NUMBER FORM 12b-25 379894108 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on F |
|
| March 11, 2016 |
gluc8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2016 (January 6, 2016) Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55439 90-1117742 (State or Other Jurisdiction (Commis |
|
| February 5, 2016 |
gluc8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 5, 2016 (February 4, 2015) Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55439 90-1117742 (State or Other Jurisdiction (Com |
|
| January 27, 2016 |
gluc8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 27, 2016 Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55439 90-1117742 (State or Other Jurisdiction of Incorporation or Org |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of registrant a |
|
| November 16, 2015 |
glucnt10q.htm UNITED STATES SEC FILE NUMBER SECURITIES AND EXCHANGE COMMISSION 000-55439 Washington, D.C. 20549 CUSIP NUMBER FORM 12b-25 379894108 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on |
|
| August 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of registrant as spe |
|
| August 14, 2015 |
glucnt10q.htm UNITED STATES SEC FILE NUMBER SECURITIES AND EXCHANGE COMMISSION 000-55439 Washington, D.C. 20549 CUSIP NUMBER FORM 12b-25 379894108 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form |
|
| August 6, 2015 |
glucex161.htm EXHIBIT 16.1 Messineo & Co., CPAs LLC 2471 N McMullen Booth Road, Suite 302 Clearwater, FL 33759-1362 T: (518) 530-1122 F: (727) 674-0511 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 June 30, 2015 Dear Sir/Madam: We have read the statements included in the Form 8-K dated June 30, 2015 of GLUCOSE HEALTH, Inc., to be filed wi |
|
| August 6, 2015 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant gluc8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2015 Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 000-55439 98-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| May 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to GLUCOSE HEALTH, INC. (Exact name of registrant as sp |
|
| May 15, 2015 |
UNITED STATES SEC FILE NUMBER SECURITIES AND EXCHANGE COMMISSION 000-55439 Washington, D. |
|
| May 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 GLUCOSE HEALTH, INC. (Exact name of Registrant as specified in its charter) NEVADA 98-0557171 (State of Incorporation or Organization) I.R.S. Employment Identification Number 609 SW 8th STREET, SUI |
|
| March 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2014 ? Transition Report under Section 14 or 15 (d) of The Securities Exchange Act of 1934 For the transition period from N/A to N/A GLUCOSE HEALTH, INC. |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 10, 2015 Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 333-147917 98-0557171 (State or Other Jurisdiction of Incorporation or Organization |
|
| December 16, 2014 |
GLUCOSE HEALTH, INC. TO UPGRADE TO OTCQB® VENTURE MARKET EXHIBIT 99.1 FOR IMMEDIATE RELEASE GLUCOSE HEALTH, INC. TO UPGRADE TO OTCQB® VENTURE MARKET WEST PALM BEACH, FL, December 16, 2014 – Glucose Health, Inc. (“GLUC” or the “Company”) today announced a series of corporate measures. First, all trading in Glucose Health, Inc. common shares will now proceed under ticker symbol GLUC, as approved by the Financial Industry Regulatory Authority (FINRA) in ac |
|
| December 16, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 15, 2014 Date of Report (Date of earliest event reported) GLUCOSE HEALTH, INC. (Exact name of registrant as specified in its charter) Nevada 333-147917 98-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 5, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 98-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of In |
|
| November 10, 2014 |
EXHIBIT 3.1 Page 1 of 4 Page 2 of 4 Page 3 of 4 EXHIBIT A Page 4 of 4 |
|
| October 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction (Commission (I. |
|
| October 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as |
|
| October 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 3, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of Inc |
|
| October 7, 2014 |
EXHIBIT 16.1 October 6, 2014 U.S. Securities and Exchange Commission Office of the Chief Accountant 100F Street Northeast Washington, DC 20549-2000 RE: Bio-Solutions Corp. File No. 333-147917 Dear Sir or Madam: We have read Item 4.01 of Form 8-K dated October 3, 2014 of Bio-Solutions Corp. and are in agreement with the statements contained therein as it pertains to our firm. We have no basis to ag |
|
| October 2, 2014 |
MANAGEMENT CONSULTANT AGREEMENT EXHIBIT 10.2 MANAGEMENT CONSULTANT AGREEMENT THIS AGREEMENT is made as of October 1, 2014 between Bio-Solutions Corp. (“Company”) and Murray Fleming (“Consultant”) and all provisions set forth in this Agreement shall govern. 1. Services. Mr. Fleming agrees to serve as the Company’s Chief Executive Officer. 2. Rate of Payment. In lieu of cash, the Company will issue Fifteen Million (15,000,000) unr |
|
| October 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of Inc |
|
| October 2, 2014 |
EXHIBIT 10.1 THIS INTELLECTUAL PROPERTY PURCHASE AGREEMENT (the "Agreement") dated this 1st day of October 2014 (the “Effective Date”), BETWEEN: BTB Management LLC whose legal address is 1712 Pioneer Avenue, Suite 5525, Cheyenne, WY, 82001(the 'Seller') OF THE FIRST PART - AND - Bio-Solutions Corp. whose legal address is 40 Easthampton B, West Palm Beach, FL, 33417(the 'Purchaser') OF THE SECOND P |
|
| August 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as spec |
|
| July 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 22, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 98-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incor |
|
| July 25, 2014 |
EXHIBIT 17.1 James Hodge Chairman of the Board of Directors Bio-Solutions Corp. Jim, Please accept my resignation as Chief Executive Officer, Chief Financial Officer, President and Chief Operating Officer of Bio-Solutions Corp. I have decided to pursue other interests. I do absolutely support Bio-Solutions Corp. and believe the Type2Defense product will help many people prevent the onslaught of Ty |
|
| July 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as spe |
|
| June 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2013 o Transition Report under Section 14 or 15 (d) of The Securities Exchange Act of 1934 For the transition period from N/A to N/A BIO-SOLUTIONS CORP. |
|
| May 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of Inco |
|
| May 5, 2014 |
EXHIBIT 16.1 April 30, 2014 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 We have read the statements that we understand Bio-Solutions Corp. (the “Registrant” or the “Company”) will include under Item 4.01 of the Form 8-K report it will file regarding the change in independent registered public accounting firms. We agree with such statements regarding our firm. Respectful |
|
| May 5, 2014 |
10-K/A 1 bisu10ka.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. 2) (Mark One) x Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2012 o Transition Report under Section 14 or 15 (d) of The Securities Exchange Act of 1934 For the transition period from N/A to N/A B |
|
| April 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. |
|
| April 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 21, 2014 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of Inco |
|
| April 15, 2014 |
EX-10.5 7 bisuex105.htm MANAGEMENT CONSULTING AGREEMENT EXHIBIT 10.5 |
|
| April 15, 2014 |
EX-10.7 9 bisuex107.htm MANAGEMENT CONSULTING AGREEMENT EXHIBIT 10.7 1 2 |
|
| April 15, 2014 |
EX-10.3 5 bisuex103.htm DAMON R DEVITT TERMINATION LETTER EXHIBIT 10.3 April 7, 2014 Damon R Devitt 16 Ann Marie Drive Saint James, NY 11780 RE: Termination of Marketing Services Agreement Dated July 24, 2013 Mr. Devitt, Bio-Solutions Corp. (the “Company”) acknowledges that the infomercial stated in the Marketing Services Agreement dated July 24, 2013 has been completed but the Company does not de |
|
| April 15, 2014 |
EXHIBIT 10.6 |
|
| April 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2013 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction of Incorporation or Organization) |
|
| April 15, 2014 |
EX-17.2 11 bisuex172.htm APPROVAL LETTER EXHIBIT 17.2 April 14, 2014 Tom, I have reviewed the contents of the Bio-Solutions Corp Form 8-K to be filed on April 15, 2014. I have no disagreement with the contents of the Form 8-K or any other disagreements with the Company. I look forward to serving the Company over the next 24 months. Best regards, /s/ William J Gallagher William J Gallagher |
|
| April 15, 2014 |
EX-10.1 3 bisuex101.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.1 |
|
| April 15, 2014 |
EX-17.3 12 bisuex173.htm LETTER OF RESIGNATION EXHIBIT 17.3 |
|
| April 15, 2014 |
EXHIBIT 3.1 1 2 |
|
| April 15, 2014 |
EX-10.2 4 bisuex102.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.2 |
|
| April 15, 2014 |
EX-17.1 10 bisuex171.htm LETTER OF RESIGNATION EXHIBIT 17.1 |
|
| April 15, 2014 |
EXHIBIT 10.4 |
|
| March 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-147917 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report |
|
| March 19, 2014 |
March 19, 2014 William H. Thompson Accounting Branch Chief Securities and Exchange Commission Re: Bio-Solution Corp. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 22, 2013 Response Dated March 6, 2014 File No. 333-147917 Dear Mr. Thompson: Thank you for your conclusions. We have reviewed your response letter dated March 22, 2014. Below are our responses. Bio-Solutions Corp reco |
|
| February 25, 2014 |
February 25, 2014 William H. Thompson Accounting Branch Chief Securities and Exchange Commission Re: Bio-Solution Corp. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 22, 2013 Response Dated January 14, 2013 File No. 333-147917 Dear Mr. Thompson: Thank-you for granting us addition time. We have reviewed your response letter dated January 14, 2014. Below are our responses. Bio-So |
|
| January 28, 2014 |
January 28, 2014 William H. Thompson Accounting Branch Chief Securities and Exchange Commission Re: Bio-Solutions Corp. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 22, 2013 Response Date: January 14, 2014 File No. 333-147917 Dear Mr. Thompson: Thank-you for your letter dated January 14, 2014. The Company requires additional time to draft a response. We do not have the funds t |
|
| January 2, 2014 |
January 2, 2014 William H. Thompson Accounting Branch Chief Securities and Exchange Commission Re: Bio-Solution Corp. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 22, 2013 Response Dates December 17, 2013 File No. 333-147917 Dear Mr. Thompson: Thank-you for the precise references in your response letter. We have reviewed your response letter dated December 17, 2013. Below are |
|
| December 4, 2013 |
December 4, 2013 William H. Thompson Accounting Branch Chief Securities and Exchange Commission Re: Bio-Solution Corp. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 22, 2013 File No. 333-147917 Dear Mr. Thompson: We have reviewed your letter dated November 20, 2013. Below are our responses. Bio-Solutions Corp recognizes that our Company is responsible for the adequacy and accur |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as |
|
| August 6, 2013 |
EXHIBIT 10.1 1 2 3 4 5 6 7 8 9 |
|
| August 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2013 Date of Report (Date of earliest event reported) BIO-SOLUTIONS CORP. (Exact name of registrant as specified in its charter) Nevada 333-147917 90-0557171 (State or Other Jurisdiction (Commission (I.R.S. Employer of Inco |
|
| August 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as spec |
|
| May 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as spe |
|
| March 22, 2013 |
EX-99.1 5 bisuex991.htm EMPLOYMENT AGREEMENT EXHIBIT 99.1 |
|
| March 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2012 o Transition Report under Section 14 or 15 (d) of The Securities Exchange Act of 1934 For the transition period from N/A to N/A BIO-SOLUTIONS CORP. |
|
| March 4, 2013 |
Exhibit 4.1 BIO-SOLUTIONS CORP. 2013 Stock Incentive Plan 1. Purpose. The purpose of the 2013 Stock Incentive Plan of Bio-Solutions Corp. is to further align the interests of employees, directors and non-employee Consultants with those of the stockholders by providing incentive compensation opportunities tied to the performance of the Common Stock and by promoting increased ownership of the Common |
|
| March 4, 2013 |
- BIO-SOLUTIONS CORP. FORM S-8 As filed with the Securities and Exchange Commission on March 1, 2013 Registration No. |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to BIO-SOLUTIONS CORP. (Exact name of registrant as |
|
| September 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 2 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-147917 Bi |
|
| August 31, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 333-147917 Bi |
|
| August 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact na |
|
| July 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact n |
|
| June 26, 2012 |
EXHIBIT 17 I, Gilles Chaumillon, do hereby tender my resignation as an officer and director of the Company effective June 20, 2012. There has been no disagreement with the Company’s other officers or directors regarding the Company’s operations or financial reporting information. /s/Gilles Chaumillon June 20, 2012 Gilles Chaumillon |
|
| June 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 20, 2012 BIO-SOLUTIONS, CORP. |
|
| May 31, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) X Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2011 Transition Report under Section 14 or 15 (d) of The Securities Exchange Act of 1934 For the transition period from N/A to N/A Commission File Number: 000-53545 Bio-Solutions Corp. |
|
| March 29, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 333-1418158 NOTIFICATION OF LATE FILING (Check One): [ X] Form 10-K [] Form 11-K [] Form 20-F [ ] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Trans |
|
| February 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 15, 2012 BIO-SOLUTIONS, CORP. |
|
| February 27, 2012 |
Exhibit 17 Mark S. Solomon Attorney at Law Fax: (954) 463-6759 Suite 300 [email protected] 901 South Federal Highway Fort Lauderdale, Florida 33316 Telephone: (954) 463-6755 February 15, 2012 Bill Gallagher 1250 NE Loop #410 San Antonio Texas 78205 Re: BISU resignation Dear Mr. Gallagher: Pursuant to our conversation, please consider this letter as my resignation as a board member of BISU. I belie |
|
| November 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 26, 2011 BIO-SOLUTIONS, CORP. |
|
| November 22, 2011 | ||
| November 22, 2011 |
Exhibit 10.1 AGREEMENT CONCERNING THE ASSET PURCHASE BY BIO-SOLUTIONS CORP. FOR THE SOLE PROPRIETORSHIP OF TYPE2 DEFENSE AGREEMENT THIS AGREEMENT ("Agreement") is made this 26 day of September, 2011, by and between BlO-Solutions Corp., a Nevada corporation ("BIO"), and Type2 Defense, a sole proprietorship based in Texas ("T2"), and the owner, William J. Gallagher of Type2 Defense ('T2") who is lis |
|
| November 21, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exa |
|
| November 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 10, 2011 BIO-SOLUTIONS, CORP. |
|
| November 14, 2011 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 333-147917 NOTIFICATION OF LATE FILING (Check One): [] Form N-SAR [ ] Form 10-K [] Form 11-K [] Form 20-F [ X] Form 10-Q For Period Ended: September 30, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Trans |
|
| September 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A-2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A-2 o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Ex |
|
| September 28, 2011 |
Bio-Solutions, Corp. [Stationary] September 26, 2011 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D. C. 20549 Attention: Re: Bio-Solutions Corp. (the ?Company?) Form 10-K/A-1 for the Fiscal Year Ended December 31, 2011 filed April 20, 2011 Form 10-Q for the Fiscal Quarter Ended June 30, 2011 filed August 22, 2011 File No. 333-147917 Dear Si |
|
| September 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A1 [?] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 333-113296 BIO-SOLUTIONS CORP. |
|
| August 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (MARK ONE) FORM 10-Q [?] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 333-113296 BIO-SOLUTIO |
|
| August 12, 2011 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 333-147917 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [] Form 11-K [] Form 20-F [ X] Form 10-Q [] Form N-SAR For Period Ended: June 30, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition |
|
| May 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (MARK ONE) FORM 10-Q [?] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2011 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 333-113296 BIO-SOLUTI |
|
| May 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (MARK ONE) FORM 10-Q [?] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2011 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 333-113296 BIO-SOLUTI |
|
| May 16, 2011 |
Washington, D.C. 20549 FORM 12b-25 Commission File Number 333-147917 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 333-147917 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [] Form 11-K [] Form 20-F [ X] Form 10-Q [] Form N-SAR For Period Ended: March 31, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transitio |
|
| April 20, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A-1 o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Ex |
|
| April 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact |
|
| March 31, 2011 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number 333-1418158 NOTIFICATION OF LATE FILING (Check One): [ X] Form 10-K [] Form 11-K [] Form 20-F [ ] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2010 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Trans |
|
| March 29, 2011 | ||
| March 29, 2011 |
As filed with the Securities and Exchange Commission on March 29, 2011 As filed with the Securities and Exchange Commission on March 29, 2011 Registration No. |
|
| November 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 biosolutionsform10q093010.htm QUARTERLY REPORT ON FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-147917 (Check One): [ ] Form 10-K [ ] Form 20-F [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2010 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Repo |
|
| August 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact na |
|
| June 25, 2010 |
Bio-Solutions Corp Grants 1/5 Dividend To Shareholders Exhibit 99.1 Bio-Solutions Corp Grants 1/5 Dividend To Shareholders Montréal, Canada, June 25th , 2010. Bio-Solutions Corp. (BISU: OTCBB), is honoured and pleased to announce that company along with company directors have unanimously decided to grant a 1 for 5 one time stock dividend. For every 5 shares an investor holds, one share will be granted by the company. These shares will be payable on Ju |
|
| June 25, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2010 Commission File Number: 333-147917 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 98- |
|
| June 25, 2010 |
Exhibit 3.1 1 |
|
| May 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact n |
|
| April 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 biosolform10k123109.htm BIO-SOLUTIONS FORM 10-K 123109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-147917 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2009 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Repor |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exa |
|
| August 18, 2009 |
Entry into a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2009 Commission File Number: 333-147917 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 9 |
|
| August 18, 2009 | ||
| August 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact na |
|
| May 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact n |
|
| May 12, 2009 |
Prospectus Bio-Solutions Corp. a Nevada corporation 5,600,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) SEC File No.333-158129 Prospectus Bio-Solutions Corp. a Nevada corporation 5,600,000 Shares of Common Stock This prospectus relates to 5,600,000 shares of common stock of Bio-Solutions Corp., which are issued and outstanding shares of our common stock, acquired by the selling security holders in private placement transactions which were exempt from the registration |
|
| May 4, 2009 |
Bio-Solutions Corp. 14517, Joseph Marc Vermette Mirabel (Qu?bec), Canada J7J 1X2 Tel: (888) 686-2611 May 4, 2009 Via Edgar Transmission Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attn: John P. Lucas Re: Bio-Solutions Corp. Registration Statement on Form S-1 Filed March 20, 2009 File No. 333-158129 Dear Mr. Lucas: Bio-Solutions Corp. (?Company?) respectful |
|
| April 23, 2009 |
S-1/A 1 biosolforms1a042209.htm BIO SOLUTIONS FORM S-1/A 042209 U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on April 22, 2009 Registration No. 333-158129 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada 0200 98 |
|
| April 23, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-K xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Soluti |
|
| April 23, 2009 |
Bio-Solutions Corp. 14517, Joseph Marc Vermette Mirabel (Québec), Canada J7J 1X2 Tel: (888) 686-2611 Bio-Solutions Corp. 14517, Joseph Marc Vermette Mirabel (Qu?bec), Canada J7J 1X2 Tel: (888) 686-2611 April 22, 2009 Via Edgar Transmission Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Attn: John P. Lucas Re: Bio-Solutions Corp. Registration Statement on Form S-1 Filed March 20, 2009 File No. 333-158129 Dear Mr. Lucas: On behalf of Bio-Solutions Corp., a Nev |
|
| March 20, 2009 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on Registration No. Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada 0200 98-0557171 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classifi |
|
| March 20, 2009 |
Exhibit 23.1 KBL, LLP 110 WALL STREET, 11th FLOOR NEW YORK, NY 10005 Consent of Independent Registered Certified Public Accountants March 20, 2009 Board of Directors Bio-Solutions Corp. We consent to the inclusion in the Registration Statement on Form S-1 of Bio-Solutions Corp. our audit report for Bio-Solutions Corp. (the “Company”) for the year ended December 31, 2008 and period March 27, 2007 ( |
|
| March 18, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2009 Commission File Number: 333-147917 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 98 |
|
| March 18, 2009 | ||
| March 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact |
|
| December 23, 2008 |
Unregistered Sales of Equity Securities SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2008 Commission File Number: 333-147917 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) |
|
| November 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 biosolform10q09308.htm BIO SOLUTIONS FORM 10Q 093008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| September 16, 2008 |
Total Annual Amount of ONS Product Purchased by BIO EX-10.1 2 exhibit10.htm LICENSE AGREEMENT BETWEEN ONS AND BIO LICENCE AGREEMENT (this “Agreement”), entered in Montreal, Quebec, Canada, as of September 11, 2008. BETWEEN: OCEANUTRASCIENCES Inc, a corporation duly incorporated in Canada, having its head office at 72, rue du Port, Matane, Quebec G4W 3M6, represented for the purpose hereof by André Rancourt, duly authorized as he so declares; (herei |
|
| September 16, 2008 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2008 Commission File Number: 333-147917 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization |
|
| August 13, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact na |
|
| May 9, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exact n |
|
| April 10, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-147917 Bio-Solutions Corp. (Exac |
|
| April 1, 2008 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D. |
|
| February 1, 2008 |
Letter from Michael Pollack CPA, LLC. Exhibit 16.1 MICHAEL POLLACK CPA 46 EQUESTRIAN LANE CHERRY HILL, NJ 08003 January 7, 2008 Mr. Roger Corriveau Chief Executive Officer Bio-Solutions Corp. 14517, Joseph Marc Vermette Mirabel (Qu?bec), Canada J7J 1X2 Dear Mr. Corriveau: Effective January 1, 2008, Michael Pollack CPA, LLC (?Pollack?) has merged into the accounting firm of KBL, LLP (?KBL?). As a result of this transaction, the client- |
|
| February 1, 2008 |
Letter from Michael Pollack CPA, LLC. Exhibit 16.2 January 31, 2008 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: I have read Bio-Solutions Corp.?s statements included under Item 4.01 of its Form 8-K filed on January 31, 2008, and I agree with such statements concerning my firm. Sincerely, /s/ Michael Pollack CPA, LLC MICHAEL POLLACK CPA, LLC |
|
| February 1, 2008 |
Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2008 Commission File Number: 333-147917 Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) |
|
| December 28, 2007 | ||
| December 28, 2007 |
Prospectus Bio-Solutions Corp. a Nevada corporation 1,066,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-147917 Prospectus Bio-Solutions Corp. a Nevada corporation 1,066,500 Shares of Common Stock This prospectus relates to 1,066,500 shares of common stock of Bio-Solutions Corp., which are issued and outstanding shares of our common stock, acquired by the selling security holders in private placement transactions which were exempt from the registr |
|
| December 7, 2007 |
Exhibit 3.2 BIO-SOLUTIONS CORP. By-Laws ARTICLE I MEETING OF STOCKHOLDERS 1. Stockholders meetings shall be held in the office of the Corporation, at Carson City, NV, or at such other place or places as the directors shall from time to time determine. 2. The annual meeting of the Stockholders of this Corporation shall be held at 11 A.M., on the 27th. day of March of each year beginning in 2008, at |
|
| December 7, 2007 |
U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on , 2007 Registration No. 333- Bio-Solutions Corp. (Exact name of registrant as specified in its charter) Nevada 0200 98-0557171 (State or other jurisdiction of incorporation or organization) (Primary Standard Indust |
|
| December 7, 2007 | ||
| December 7, 2007 |
Exhibit 3.1 Articles of Incorporation of BIO-SOLUTIONS CORP. FIRST. The name of the corporation is: BIO-SOLUTIONS CORP. SECOND. Its principal office in the State of Nevada is located at 251 Jeanell Dr. Suite 3, Carson City, NV 89703, although this Corporation may maintain an office, or offices, in such other place within or without the state of Nevada as may from time to time be designated by the |
